GlassScriptPhysician profile
Jennifer M Jones
NPI 1972528040
$2,320.98
in general payments reported to CMS, 2019-2025
23 companies · $634 in 2025
The $634 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.84 · 2020: $218 · 2021: $288 · 2022: $390 · 2023: $315 · 2024: $461 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $770.17 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $217.65 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $161.13 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $131.60 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.91 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $105.75 | 2025 | Wegovy |
| Amgen INC. | $103.44 | 2020-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $95.36 | 2024-2025 | Watchman Access System, General - Therapies |
| Janssen Pharmaceuticals, INC | $91.04 | 2020-2023 | Xarelto |
| Kestra Medical Technology Services, INC. | $85.19 | 2024-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $82.76 | 2021-2024 | Keytruda, Verquvo |
| Medtronic, INC. | $67.12 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $51.93 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $49.58 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $35.70 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.13 | 2021 | |
| Esperion Therapeutics, INC. | $21.58 | 2020 | |
| Genzyme Corporation | $19.32 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $17.94 | 2024 | Farxiga |
| Glaxosmithkline, LLC. | $17.87 | 2022 | |
| Impulse Dynamics (USA) INC. | $17.22 | 2025 | Optimizer |
| Sanofi Pasteur INC. | $15.14 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.